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Abstract
Purpose—Researchers are often interested in estimating treatment effects in subgroups
controlling for confounding based on a propensity score (PS) estimated in the overall study
population.
Objective—To evaluate covariate balance and confounding control in sulfonylurea (SU) versus
metformin (MET) initiators within subgroups defined by cardiovascular disease history (CVD)
comparing an overall PS with subgroup-specific PSs implemented by 1:1 matching and
stratification.
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Methods—We analyzed younger patients from a US insurance claims database and older
patients from two Medicare (Humana Medicare Advantage, fee-for-service Medicare Parts A, B
and D) datasets. Confounders and risk factors for acute myocardial infarction (AMI) were
included in an overall PS and subgroup PSs with and without CVD. Covariate balance was
assessed using the average standardized absolute mean difference (ASAMD).
Results—Compared to crude estimates, ASAMD across covariates was improved 70–94% for
stratification for Medicare cohorts and 44–99% for the younger cohort, with minimal differences
between overall and subgroup-specific PSs. With matching, 75–99% balance improvement was
achieved regardless of cohort and PS, but with smaller sample size. Hazard Ratios within each
CVD subgroup differed minimally among PS and cohorts.
Conclusion—Both overall PSs and CVD subgroup-specific PSs achieved good balance on
measured covariates when assessing the relative association of diabetes monotherapy with
nonfatal MI. PS matching generally led to better balance than stratification, but with smaller
sample size. Our study is limited insofar as crude differences were minimal, suggesting that the
new user, active comparator design identified patients with some equipoise between treatments.
Keywords
Comparative effectiveness research; new user design; propensity scores
INTRODUCTION
In comparative effectiveness research, covariate selection is critical in deriving propensity
scores (PSs) to control for confounding [1–5]. However, the effect of covariates on
treatment may vary by subgroup. The impact of using a PS estimated in the overall cohort
for pre-specified subgroup analyses is not well understood. There may be efficiency and
validity gains in estimating separate PSs for different subgroups but subgroup-specific PS
derivation within multiple subgroups may not be practical, and correct specification of PS
with multiple subgroups may be difficult, resulting in greater imbalances.
A recent study assessed whether using an overall cohort PS in subgroup analyses was
feasible, finding that a cohort PS resulted in similar effect estimates as a subgroup-specific
PS when the overall cohort PS is correctly specified, especially in larger subgroups [6]. That
study focused on simulations and a specific example of antipsychotics and short term
mortality in two cohorts, however, and NSAIDS and severe gastrointestinal complications in
one cohort. In patients with type 2 diabetes mellitus (T2DM), there is mixed evidence about
the risk of myocardial infarction (MI) associated with sulfonylureas (SU) relative to
metformin (MET) [7–9]. An important potential confounder for such analyses is history of
cardiovascular disease (CVD) [10]. In this study, we extended the empirical work of Rassen
[6] to T2DM using the design of the mini-Sentinel protocol [10]. We used three different
administrative databases to assess the association of initiating SU vs MET monotherapy
(new users) on nonfatal MI after conditioning (e.g., matching or stratifying) on PSs derived
within an overall cohort compared to conditioning on CVD subgroup-specific PSs with
different conditioning approaches.
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We studied younger (aged < 65 years) patients from a large, US-based administrative claims
database of a commercially insured population and their dependents (Clinformatics
DataMart, OptumInsight™ previously known as i3 InVision™ Data Mart, Ingenix, Inc).
This database is used extensively for pharmacoepidemiological research and contains more
than 45 million unique members spanning almost 10 years, of which more than 29 million
patients were continuously enrolled for at least 12 months.
We also studied older adults from Humana (Humana MA) with Medicare Advantage
Prescription Drug plans (MAPD), who had both pharmacy and medical claims, and
prescription drug plan (PDP) claims. In 2010, Humana had over 3.2 million Medicare
members including 2 million Medicare Advantage members, and there has typically been
little plan turnover [11].
Finally, older adults from an approximate 20% random sample of Medicare beneficiaries 65
years or older enrolled in the stand-alone prescription drug plan (PDP) and fee-for service
(FFS) components of Medicare claims data (Medicare FFS) from 1/1/2007 to 12/31/2009
were analyzed for this study [12–13].
Within the commercially insured younger cohort, we identified adult patients aged 25–64
years with T2DM who were initiating monotherapy with SU or MET. In Humana Medicare
Advantage and Medicare FFS claims, we identified new users of the same therapies who
were >=65 years old. T2DM was identified as those with at least one of the following: a) at
least one inpatient admission for which the principal diagnosis was recorded as diabetes; b)
at least one inpatient admission for which any diagnosis was recorded as diabetes coupled
with another criterion (oral antihyperglycemic agent (OHA) prescription, inpatient or
outpatient type 2 diabetes diagnoses, or laboratory result); c) at least two outpatient facility
or physician office visit claims for which a diagnosis was recorded as diabetes; d) at least
one inpatient or outpatient claim of diabetes AND at least one prescription of OHA
medication; or e) at least one laboratory result of blood glucose>200 mg/dl OR HbA1C >
6.5% [14–15]. Data were extracted for patients with T2DM with claims between January 1,
2003 and December 31, 2010 for the commercially insured (6-month look-back period to
July 1, 2002), Jan 1, 2008 to July 31, 2011 for Humana MA (6-month look-back to July 1,
2007) and from July 1, 2007 to Dec 31, 2009 in the Medicare FFS (6-month look-back
period to Jan 1, 2007).
Patients were excluded if they met any of the following: a) type 1 diabetes (identified by the
5th digit number of ICD-9 code), juvenile diabetes, malnutrition-associated diabetes, drug-
induced diabetes or gestational diabetes at any time in the database without subsequent type
2 diabetes code, or ketoacidosis; b) 25 years or younger at first notation of a diabetes code;
c) diabetes ICD-9 code associated with a blood draw within 15 days with corresponding
laboratory data indicating the glucose and HbA1C results did not meet criteria for diabetes,
and no prior or subsequent diabetes codes or OHA use; d) any OHA prescription within 7
months prior to index date (first prescription of SU or MET during the study window); e)
not having both medical and pharmacy benefits. SU and MET were identified using NDC
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codes recorded as part of paid prescription claims; hence, it is assured that the physician
prescribed and the pharmacy filled the prescription.
Eligibility in terms of initiation of monotherapy required at least two consecutive
prescriptions of MET or SU within 120 days. This improves the likelihood that the patient
actually took the product given it was refilled. No patients meeting this criteria were
excluded. Follow-up began at the 2nd qualifying prescription and continued until the patient
experienced an MI or was censored at the earliest occurrence of: (1) end of patient’s
enrollment or death, or (2) end of the study window. Patients who transitioned to Medicare
during follow-up in the younger cohort were censored at transition. In the primary analysis,
patients were not censored if they switched, discontinued or augmented treatment with one
of the drugs being compared. However, similar results were found in a secondary ‘as
treated’ analysis where patients were censored when they discontinued drug, switched or
augmented with SU or MET. Stopping was defined as having no additional prescription
within the days supply plus a grace period of 30 days after the previous prescription.
The primary outcome of nonfatal acute myocardial infarction (AMI) was defined as a
diagnosis based on hospital discharge ICD-9 code: 410.x0 or 410.x1 in the first or second
position, or DRG codes 121, 122, 123 [10]. No length of stay criterion was applied. Other
cardiovascular outcomes typically included in composite endpoints of cardiovascular
outcomes trials are typically not available in databases (fatal MI, other cardiovascular
death), and revascularizations, unless urgent (distinction not available in database), are
typically considered a ‘soft’ outcome subject to substantial geographic variability and
physician subjectivity. Hence, these outcomes were not studied.
The primary subgroup was defined as history of cardiovascular disease in the prior 6
months. History of cardiovascular disease included any cardiovascular disease, i.e., MI,
CABG, PTCA, unstable angina and peripheral arterial disease (PAD) [10]. In addition, we
included the following as prevalent CVD: lower extremity revascularization (38.18),
endarterectomy (39.25, 39.29), lower extremity bypass (84.10 – 84.17), and procedure codes
for carotid revascularization (38.11, 38.12), endarerectomy (00.61, 00.63), carotid bypass
(39.28).
Baseline comorbidities were determined by ICD-9 codes in the 6-month period before the
index date, and included complications of diabetes, cardiovascular disease, liver disease,
lung disease, infection, cancer and other diseases. Confounders and risk factors for nonfatal
MI included in the PS models were selected using prior clinical and epidemiologic
knowledge based on published literature (a priori), and consisted of age, sex and diagnoses
(coded at the 3-digit level), procedures, and drugs (coded based on generic drug name) that
had a prevalence of >2% and <98% in the 6-month baseline period to allow evaluation of
which individually had the greatest imbalance. Also included in the traditional Medicare
analyses were nursing home residence, number of hospitalizations, emergency department
visits, number of outpatient physician visits, and number of distinct prescription drugs
dispensed. Interactions were not accounted for in derivations of PS, since the main effects
PS model balanced the groups fairly well. In the base-case scenario, we only included
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variables available in all three databases. In Medicare analyses, sensitivity analyses
including variables unique to that database showed similar results.
Within each database population, we estimated three separate PS for predicting treatment
initiation with SU versus MET: an overall PS (including prior CVD as a covariate) and 2
separate PSs for the prior CVD subgroups. We implemented these PS within each subgroup
of CVD using a greedy algorithm for 1:1 matching [16] and equally-sized PS deciles
(quintile for Medicare FFS) stratification after restricting to an overlapping PS range.
Because the true effect (necessary to compare bias) is unknown in these empirical datasets,
we primarily compared the balance within CVD subgroups based on the overall vs.
subgroup-specific PS. We also compared overall vs. subgroup-specific PSs with respect to
the point estimate of the hazard ratio (HR) and 95% confidence interval width for treatment
with SU vs. MET. The average standardized absolute mean difference (ASAMD) was used
to assess balance within CVD subgroups [17–19], with lower ASAMD indicating better
balance. For the matched analyses, the ASAMD was calculated as the absolute value of the
difference in means (percentages) divided by a pooled standard deviation for each covariate,
averaged across covariates. For the stratified analyses, we first calculated the ASAMD for
each covariate within each PS stratum and then combined differences within covariate
across strata, finally averaging over all covariates. We used Kaplan Meyer plots to assess the
proportional hazards assumption and fit Cox proportional hazards models for time to event
(acute non-fatal MI) over the entire follow-up if appropriate (PH assumption met).
RESULTS
Younger cohort
Baseline characteristics of the younger cohort were generally comparable for MET and SU
monotherapy new users, with the most pronounced differences at baseline before matching
observed in gender, age, cardiovascular and renal diseases, non-skin cancers and retinopathy
(Table 1).
There was minimal non-overlap between propensity scores overall (Figure 1), reflecting
minimal imbalance in this younger cohort (crude average standardized absolute mean
difference (ASAMD) in subgroups without CVD history: 0.073, and with prior CVD:
0.099). CVD history was related to SU vs MET treatment in the PS model (1.49 (1.45,
1.53)). With matches achieved for over 98% of the SU patients, baseline covariates were
fairly well balanced with overall PS for the full cohort and within the subgroup without
CVD history (ASAMD: 0.01 for both) as well as when the subgroup-specific PS was used
(ASAMD: 0.01 for subgroup without CVD history) (Figure 2). Within the prior CVD
subgroup where 92% of SU patients were matched, balance was only slightly better using
the subgroup-specific PS (ASAMD: 0.01) than using the overall PS (ASAMD: 0.02).
With PS stratification, balance was achieved with both overall PS (ASAMD: 0.04) and
subgroup-specific PS (ASAMD: 0.02) within the subgroup without CVD history, as well as
in the subgroup with CVD history (ASAMD: 0.02 for both overall and subgroup-specific
PS). ASAMD estimates were consistently lower for 1:1 matching than for stratification.
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The crude HRs for non-fatal MI in the younger cohort with SU vs MET were 1.08 (1.05,
1.11) overall, 1.08 (1.04, 1.11) within the subgroup with no prior CVD history, and 1.05
(0.99, 1.13) for those with prior CVD (Figure 3). HR estimates were highly consistent (HR
range: 1.1–1.15) between overall and subgroup-specific PS for 1:1 matching, differing by
<1% in those without prior CVD, and only 3.5% in those with prior CVD. PS stratification
showed similar patterns.
Older Medicare cohorts
Baseline characteristics of the older cohorts were less similar than for the younger cohort,
with the most pronounced differences before matching observed in age, gender, heart
disease (prior MI, peripheral vascular disease, pacemakers, congestive heart failure), renal
disease, bone fractures, and diabetes complications, likely due to the higher proportion of
older age (>80 years) in SU users (overall (ASAMD): 0.35 in Humana MA, 0.11 in
Medicare FFS) (Table 2). CVD history was related to treatment in the PS model (1.60 (1.56,
1.64) for Humana MA; (1.27 (1.20, 1.33)) for Medicare FFS). Only 82% to 88% of the SU
patients overall were matched. Balance was achieved with 1:1 matching in Humana MA for
those without prior CVD where 90% of SU patients were matched (AMASD: overall PS:
0.01; subgroup-specific PS: 0.001), but imbalance was somewhat greater for patients with
prior CVD where only 72% of SU patients were matched (overall PS: AMASD: 0.01,
subgroup-specific PS: 0.01). PS distributions after matching were superimposable, however
(not shown). For Medicare FFS, balance was achieved for those without prior CVD where
96% of SU initiators were matched (ASAMD using overall PS: 0.0185; ASAMD using
subgroup-specific PS: 0.01) and among patients with prior CVD where only 84% of the SU
users were matched (ASAMD overall PS: 0.01; subgroup-specific PS: 0.01). Again, PS
distributions were superimposable. In both subgroups, balance was only minimally better
with the subgroup-specific PS compared to overall PS.
For stratified analyses, balance in the Humana MA cohort using subgroup-specific PS
(AMASD: 0.034) was almost identical to using overall PS (0.03) for subgroup without prior
CVD as well as for the subgroup with CVD history (subgroup-specific PS AMASD: 0.03
and overall PS AMASD: 0.02). For Medicare FFS stratified analyses, balance was
comparable among those without prior CVD (ASAMD overall PS: 0.03; subgroup-specific
PS: 0.04) as well as among those with prior CVD (0.03 and 0.03 for overall and subgroup-
specific PS). ASAMD estimates were lower for matching than for stratification across
subgroups and cohorts.
Crude HR estimates (± 95% CI) for non-fatal MI with SU vs. MET were higher for the older
cohorts (HR: 2.1 (1.9–2.3) for Humana MA and HR: 2.2 (1.9–2.5) for Medicare FFS) than
for the younger cohort (Figure 3). HR estimates were consistent between overall and
subgroup-specific PS for 1:1 matching within those without prior CVD (HR: 1.4–1.9) and
those with prior CVD (HR: 1.5–1.7), differing by 3–8% within the older cohorts. PS
stratification showed similar patterns, differing by <1% within subgroups. Including race
(not available in other datasets) in PS derivation for FFS did not change results.
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Based on U.S. cohorts of younger and elderly T2DM patients initiating MET or SU, an
overall PS balanced nearly as well in matching within subgroups as a subgroup-specific PS
in assessing the association between monotherapy and MI. After PS implementation,
subgroup-specific PS showed slightly better balance within the subgroup with prior CVD,
but the differences were small, and HRs for MI were highly consistent across cohorts,
regardless of whether matching or stratification was applied or overall vs subgroup-specific
PS was used.
If the relationship between covariates and treatment varies by a strong confounder, a
subgroup-specific PS could potentially provide better balance covariates in subgroup
matched analyses, especially when the influence of covariates on treatment selection is not
comparable across subgroups. In our case, particularly in the younger cohort, baseline
differences between groups were minimal, perhaps reflecting the new user (initiators of
therapy) design applied and the assessment of monotherapy, resulting in predominantly
newly diagnosed T2DM with minimal complications and comorbidities. Even in the elderly
diabetes cohorts, differences between groups were not pronounced despite greater
prevalence of comorbidities and complications. The lower prevalence of cardiovascular
disease in the younger cohort may help explain the somewhat greater imbalance observed
with stratification methods, and the consistency in HRs for this cohort.
We hypothesized that CVD history could be a strong confounder given its strong predictive
properties for nonfatal AMI and CV outcomes in general, and the potential to influence
prescribing of oral anti-hyperglycemic agents [10]. A few studies have suggested that MET
may reduce cardiovascular risk, while other studies suggest that mortality may be increased
with use of SU [7–9]. We assessed the strength of the association of CVD history with SU
and MET initiation, and found it to be moderately but significantly associated. CVD history
may be of greater importance in the Humana cohort, given the significant reduction in
ASAMD when stratifying by CVD subgroup.
This study included patients treated with SU or MET monotherapy who were naive to
diabetes pharmacological treatment. However, treatment complexity in diabetes is strongly
related to duration of diabetes and microvascular complications, and also to cardiovascular
outcomes. We expect that a greater degree of confounding would be more likely in patients
with longer duration diabetes and with more complex treatment regimens. In addition, we
expected significant channeling bias due to concerns about hypoglycemia when adding SU
to existing diabetes regimens in patients with longer term diabetes, especially in the elderly.
We did not assess more complex regimens of SU or MET initiators on a background of
other diabetes therapies as our objective was to study monotherapy and MET is
overwhelmingly used first-line.
Our results are in agreement with Rassen et al [6], who showed that a correctly specified
cohort PS can be applied in subgroup analyses, based on simulations and two empirical
examples. This was supported by small differences (<10%) in estimated log odds ratios in
empirical analyses when the full cohort PS was applied to a subgroup analysis, similar to our
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findings. Differences were larger with small subgroups (n<1000) or rare outcomes, which
was confirmed in simulation analyses. However, the strength of confounding with the
subgroups they assessed (gender, age and risk) was unclear, whereas we report the
association of CVD in the PS model. In addition, their simulations were based on outcome
model adjustment for PS, not on applying 1:1 PS matching and stratification, as in our
analyses. Neither of our studies included interactions in modeling PS, an area that deserves
further research. However, because of the consistency of our findings between overall and
subgroup-specific PS, adding interactions would be unlikely to change our results. Finally,
our results address an important methodological question in the area of diabetes, and one
highly relevant to the mini-Sentinel protocol.
Certain limitations should be considered in interpreting these results. Our analyses are based
on a younger and two elderly cohorts with T2DM, in three separate claims databases, which
could not be combined due to inherent differences in the populations. Generalizability is
hence limited to the insured in the younger group, and in the elderly, to those who choose
the Medicare Advantage or FFS plans. We did not have information on ethnicity except in
Medicare FFS where it appeared to not influence results. Balance was assessed using the
commonly used ASAMD which has the advantage of being an overall balance metric, but
does not account for strength of association to outcome. However, we included the most
important confounders in PSs which indirectly assures inclusion of covariates associated
with outcome. The small reductions in ASAMD with the various techniques are difficult to
interpret without standards, and could benefit from further research. Finally, information on
fatal MI, other cardiovascular deaths and other cardiovascular events were not available.
Our primary goal to assess differences when applying an overall vs a subgroup-specific PS,
not to assess differences in AMI between SU vs. MET per se. Results may be dependent on
the disease, outcome and confounder as well as the exposures studied. Further research is
needed through other empirical examples and simulations in which the covariates may have
different relationships with the potential subgroup variable.
The strengths of our analyses are that three separate claims databases and two age cohorts
were analyzed, and several approaches to control for confounding were used. These cohorts
and the available information on medical history, prior and concomitant therapies, and
comorbidities, reflect the types of studies in which propensity score methods are typically
applied to control for confounding in comparative effectiveness research.
CONCLUSION
In this study, balance of baseline covariates between treatment groups was achieved with
both overall cohort and subgroup-specific PSs in analyses of the effect of SU versus MET
monotherapy with nonfatal MI in diabetes patients across three cohorts and within and
across CVD subgroups, with only minimally better balance for subgroup-specific PSs.
Matching achieved better balance than stratification on PS but with expected loss in sample
size. Our study is limited insofar as crude differences were minimal, suggesting that the new
user, active comparator design identified patients with some equipoise between treatments.
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• The active comparator, new user study design limited baseline covariate
differences between sulfonylurea and metformin monotherapy initiators with
type 2 diabetes mellitus prior to PS implementation.
• We found little indication for differential channeling between sulfonylureas and
metformin in patients without CVD and with CVD.
• Balance of covariates across treatments was achieved with both overall and
subgroup-specific PSs using matching and stratification in three different
cohorts.
Girman et al. Page 11























Girman et al. Page 12























Girman et al. Page 13























Girman et al. Page 14

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Med Care. Author manuscript; available in PMC 2015 March 01.
